A new retraction notice in the Journal of Applied Physiology gives only a hint at the problems in the paper, but what it does say has led us to a story about one of its co-authors.
We’ve written before about retractions for cell lines that turn out not to be what researchers thought they were. In a few cases, that has involved contamination by HeLa cells, named for Henrietta Lacks. Today, we note the retraction of a paper whose authors, from Taiwan, thought they were using human muscle cells that line blood vessels when they were actually studying such cells from rat embryos.
Midsagittal image of the anatomy of sexual intercourse, from BMJ http://bit.ly/v2ZkxQ
Yesterday we reported on the retraction for data misuse and plagiarism of a 21-year-old paper on sex and female cancer patients. Turns out we missed a couple of rather interesting details about the authors of the pulled article.
Leukemia & Lymphoma has retracted 2004 paper by a group of authors in Mexico after concluding that, well, the article never should have been accepted to begin with.
The Annual Review of Sex Research (which is a supplement to the Journal of Sex Research) has retracted a 1992 paper by a group of researchers who lifted much of their analysis from two even older articles by another scholar. At 21 years post-publication, this is one of the oldest — but not the record-oldest — retractions we’ve covered to date.
The pulled paper, “Sexuality and cancer in women,” came from Willibrord C. M. Weijmar Schultz, Harry B. M. Van de Wiel, Daniela E. E. Hahn, and Mels F. Van Driel. (Weijmar Schultz and Van de Wiel are co-authors of this rather curious passage about the appropriateness of sexual contact between doctors and patients:
Last month, Ivan met David Vaux at the 3rd World Conference on Research Integrity in Montreal. David mentioned a retraction he published in Nature, and we thought it would be a great guest post on what it’s like to retract one of your own papers in an attempt to clean up the literature.
David Vaux
In September 1995 Nature asked me to review a manuscript by Bellgrau and co-workers, which subsequently appeared. I was very excited by this paper, as it showed that expression of CD95L on Sertoli cells in allogeneic mismatched testes tissue transplanted under the kidney capsule was able to induce apoptosis of invading cytotoxic T cells, thereby preventing rejection. As I wrote in a News and Views piece, the implications of these findings were enormous – grafts engineered to express CD95L would be able to prevent rejection without generalized immunosuppression.
In fact, I was so taken by these findings that we started generation of transgenic mice that expressed CD95L on their islet beta cells to see if it would allow islet cell grafts to avoid rejection and provide a cure for diabetes in mismatched recipients.
Germans and Italians are big masterbatchers. Click to enlarge. via http://bit.ly/100YBKB
Our mothers told us that if we used the masterbatch process, we’d go blind. And what better way to gather some updates to recent posts than to include one that involves said masterbatch process?
In what could be a significant blow to a major pharmaceutical company, Nature Medicine is reportedly set to retract a 2010 article by a group of researchers affiliated with a Chinese arm of the drug giant GlaxoSmithKline.
We’re not the first to report the news — you can read coverage of it on In the Pipeline and Pharmalot, for starters — which includes the revelation that Glaxo has fired Jingwu Zang, a co-author of the suspect paper and former senior vice president and head of research and development at the Shanghai facility: in other words, a big fish. (Big enough to have a profile in, well, Nature Reviews Drug Discovery.)